AMH Test: What It Measures and What Your Results Mean | Damien Fertility Partners
According to CDC ART surveillance data, ovarian reserve testing is now a standard component of nearly every fertility workup in the United States. Yet AMH — anti-Müllerian hormone — remains one of the most misread numbers a patient will encounter. A result comes back low, or high, and the interpretation is often handed over without enough context to make it useful.
You’re likely here because you have a number and you’re not sure what to do with it. That’s the right question to be asking. We’ve spent over 35 years helping patients across New Jersey — from our offices in Shrewsbury, Newark, and Jersey City — interpret results like these and translate them into a clear plan. An AMH value is a data point. What matters is how it’s read.
AMH Measurements
Anti-Müllerian hormone is a protein produced by the granulosa cells surrounding small, early-stage follicles in the ovaries. Unlike estradiol or FSH, AMH remains relatively stable throughout the menstrual cycle, which means the test can be drawn on any cycle day — a practical advantage that makes it easier to schedule without coordinating around day 3.
What the number reflects is the size of the remaining follicle pool — a proxy for how many eggs are left. It does not measure egg quality. It does not assess whether eggs are chromosomally normal. It does not evaluate ovulation, tubal function, or uterine receptivity.
Think of AMH as a quantity gauge, not a fertility score. The distinction matters more than most patients are told. For a full picture of what evaluation and diagnosis involves, our team walks through every component at your first visit.
AMH Reference Ranges
AMH is measured in nanograms per milliliter (ng/mL). Reference ranges vary slightly between laboratories, but a general framework looks like this:
Normal range. An AMH between 1.0 and 3.5 ng/mL is considered within normal range for most women of reproductive age. This suggests an ovarian reserve appropriate for stimulation and family planning discussions.
Low range. Levels below 1.0 ng/mL indicate diminished ovarian reserve. Levels below 0.5 ng/mL are considered very low. This signals a smaller follicle pool — not an absence of pregnancy potential, but a reason to prioritize evaluation sooner rather than later.
Elevated range. Levels above 3.5 ng/mL reflect a larger-than-average follicle pool. Above 5.0 ng/mL, the clinical picture changes — see the PCOS section below.
These ranges are a starting point. They are not a verdict without age and clinical context alongside them.
Low AMH
A low AMH is not a diagnosis of infertility. It indicates that the ovarian reserve is smaller than expected for your age, which has real implications for treatment planning — but it does not foreclose natural conception or IVF success.
What low AMH does tell us, specifically, is how the ovaries are likely to respond to stimulation medications. A patient with low AMH may produce fewer eggs per retrieval cycle than a patient with a normal or high AMH. That information directly shapes protocol design: medication type, dosing, and cycle expectations all adjust accordingly.
What low AMH does not tell us is whether you will conceive. Large, well-designed studies — including the EAGeR trial, one of the most rigorous on this question — found that women with low, normal, and high AMH had virtually identical rates of natural conception. AMH did not predict fecundability or time to pregnancy in that population. Many patients with low AMH conceive naturally. Others conceive with IVF or IUI. The number opens a conversation about timing and treatment approach; it does not close one about outcome.
If your AMH is low, the most useful response is evaluation — not alarm. That means a complete ovarian reserve workup, not a single number reviewed in isolation.
High AMH
A higher AMH is often assumed to be good news. It can be — but context applies here as much as it does for low results.
PCOS and elevated AMH. In polycystic ovary syndrome (PCOS), the ovaries contain a large number of small, immature follicles, each contributing to the AMH reading collectively. The result is an elevated — sometimes sharply elevated — AMH that reflects follicle count rather than normal follicular development. Many of those follicles do not mature and release eggs in a normal ovulatory cycle, which can contribute to irregular ovulation and difficulty conceiving despite the high number. Ovulation induction is often the first treatment step evaluated in this context.
If your AMH is above 5.0 ng/mL, PCOS is a clinical consideration worth evaluating, even in the absence of other symptoms.
Ovarian hyperstimulation risk. For patients pursuing IVF, a high AMH indicates elevated risk of ovarian hyperstimulation syndrome (OHSS) — an excessive response to stimulation medications that can range from uncomfortable to medically serious. Knowing AMH before designing a stimulation protocol allows us to adjust medication dosing and monitoring intervals to reduce that risk. At our practice, AMH results are always reviewed alongside antral follicle count (AFC) ultrasound findings and a full hormonal panel before any stimulation protocol is finalized.
Age Impact
AMH naturally declines with age as the follicle pool diminishes. The same number carries different clinical weight depending on when in a woman’s reproductive life it appears.
An AMH of 1.2 ng/mL in a 38-year-old may be appropriate for her age group — a result that warrants monitoring and timely planning, but not alarm. The same result in a 27-year-old signals diminished ovarian reserve for her age and calls for more immediate evaluation and conversation about family planning timelines.
This is why AMH results should never be interpreted against a single universal threshold. Age is the critical variable. Without it, the number is incomplete. Our success rates are reported by age group for exactly this reason.
AMH as Part of a Complete Ovarian Reserve Assessment
AMH is one marker in a panel, not a standalone test. A complete ovarian reserve evaluation includes:
Antral follicle count (AFC). An ultrasound-based count of small follicles visible in both ovaries at the start of a cycle. AFC provides a direct visual estimate of the resting follicle pool and is interpreted alongside AMH to give a more complete picture. A low AMH paired with a normal AFC, for example, may suggest a more reassuring outlook than either result read alone.
Day 3 FSH and estradiol. Follicle-stimulating hormone (FSH) and estradiol drawn on cycle day 3 provide additional information about ovarian function and pituitary signaling. Elevated day 3 FSH in particular can indicate diminished ovarian reserve independent of AMH.
Together, these markers give a more complete and reproducible picture than any single value. Over-reliance on AMH — in either direction — risks both unnecessary anxiety and unwarranted reassurance. Our evaluation and diagnosis process always incorporates the full panel before any treatment recommendation is made.
Where AMH Is Most Predictive: IVF Planning
AMH performs best as a clinical tool in one specific context: predicting ovarian response to stimulation in IVF. It helps anticipate how many eggs are likely to be retrieved, informs medication selection and dosing, and allows for early protocol adjustments when response differs from expectation.
In our practice, AMH is reviewed as part of a full pre-cycle evaluation — alongside AFC, FSH, estradiol, and a thorough history — before any stimulation protocol is designed. Our CAP-accredited laboratory, operating under FDA and NJ Department of Health oversight with zero-deficiency findings, processes these panels in-house, which means results and protocol decisions move without delay. We also use CHLOE by Fairtility — AI-powered embryo monitoring in embryoscope time-lapse incubators — to support embryo selection once retrieval is complete.
For patients with low AMH considering IVF, this kind of individualized protocol design is where the number becomes most actionable. It does not predict whether IVF will succeed; it informs how stimulation should be approached. Patients who are not candidates for standard IVF may also want to explore donor egg IVF as an option.
Get AMH Tested Proactively
Many women choose AMH testing before they begin trying to conceive — particularly if they are considering delaying childbearing or evaluating whether fertility preservation is worth pursuing. Egg freezing decisions benefit from knowing where reserve stands relative to age-matched expectations.
AMH alone does not predict natural fertility, and a result outside normal range should not be treated as a fertility forecast. But for long-term family planning conversations — especially those involving timing, treatment, or preservation — it provides useful information that a specialist can put in context.
The 2024 New Jersey insurance mandate expansion now requires coverage for fertility testing and treatment under group plans covering 50 or more employees, with up to four retrievals per lifetime covered and prior restrictions on age and sexual orientation removed. Our Insurance and Financial Resources page outlines what qualifying plans cover, and financing options are available for costs not covered by insurance.
Frequently Asked Questions
1. What is a normal AMH level?
A normal AMH for women of reproductive age generally falls between 1.0 and 3.5 ng/mL, though reference ranges vary by laboratory. The number is most meaningful when interpreted against your age and alongside AFC and day 3 hormonal values — not read against a single universal threshold. Our team reviews all values together as part of a complete evaluation.
2. Can I still get pregnant with a low AMH?
Yes. Low AMH indicates a smaller ovarian reserve, not an inability to conceive. Rigorous studies, including the EAGeR trial, found no meaningful difference in natural conception rates between women with low, normal, and high AMH. What low AMH does suggest is that evaluation and planning should not be delayed. Request a consultation to discuss next steps.
3. Do AMH levels change over time?
AMH naturally declines with age as the follicle pool diminishes. Short-term fluctuation between tests is possible, but a consistently low AMH is unlikely to improve significantly on its own. No intervention has been proven to meaningfully raise AMH levels, though optimizing overall health and addressing conditions like PCOS may support ovarian function.
4. Does a high AMH mean I’m more fertile?
Not necessarily. Elevated AMH — particularly above 5.0 ng/mL — is frequently associated with PCOS, in which ovulatory dysfunction can make natural conception more difficult despite the high follicle count. High AMH also increases OHSS risk during IVF. A specialist should interpret the result in full clinical context.
5. Does AMH testing require a specific cycle day?
No. One practical advantage of AMH is that it can be drawn on any day of the menstrual cycle. Unlike FSH and estradiol, which require day 3 timing, AMH levels remain relatively stable throughout the cycle — making it easier to schedule as part of an initial evaluation.
6. Is AMH testing covered by insurance in New Jersey?
Coverage depends on your plan and clinical indication. Under the 2024 New Jersey mandate expansion, qualifying group plans covering 50 or more employees are required to cover fertility evaluation and treatment. Our bilingual Insurance Verification Specialist can confirm your specific coverage before your appointment. See our Insurance and Financial Resources page for more detail.
7. Should I get an AMH test if I’m not ready to have children yet?
Many women choose AMH testing proactively — particularly if they are considering fertility preservation or want to understand their reproductive timeline before beginning to try. While AMH alone does not predict natural fertility, it can inform a useful long-term planning conversation with a specialist. Request a consultation to discuss whether proactive testing makes sense for you.
After Your AMH Test
An AMH result handed over without interpretation is not useful. What matters is what surrounds it: your age, your cycle history, your antral follicle count, your FSH and estradiol, and your reproductive goals.
We review every AMH result in that full context before making any recommendation. Whether your number is reassuringly normal, unexpectedly low, or elevated in a way that raises a question about PCOS, the next step is a complete clinical picture — not a reaction to a single value.
Dr. Miguel Damien and Dr. Barry Perlman are both board-certified in reproductive endocrinology and infertility by the American Board of Obstetrics and Gynecology — a credential that not every “fertility specialist” holds. Dr. Damien has been named a Castle Connolly Top Doctor in the NY Metro Area six times (2005, 2007, 2008, 2010, 2017, 2018). Virtual consultations are available with Dr. Perlman for patients who prefer remote evaluation. Our in-house surgeon, Dr. Nina Seigelstein, handles any surgical evaluation without referring patients out.
Request a consultation at our Shrewsbury (Monmouth County), Newark (Essex County), or Jersey City (Hudson County) offices to review your results, complete a full ovarian reserve assessment, and build a plan that reflects your clinical picture and your goals.